Quotes

Company Overview

Financial Analysis

Main Composition Key Indicators Financial Statement

Multi-dimentional Analyses

Company Valuation Capital Tracking Short Selling Data

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

CEO： Castagna Pharm.D., Michael E.

Market： NASDAQ

Hot List

TradeSearchNews

SymbolLatest price%Chg

Moomoo > Quotes > MNKD MannKind > Detailed Quotes

MNKD MannKind

4.170+0.490+13.32%

Close 05/23 19:28 ET

4.350+0.18+4.32%

Post Mkt Price 05/23 19:37 ET

High

4.770

Open

3.730

Turnover

105.89M

Low

3.570

Pre Close

3.680

Volume

25.42M

Post-Market

Price Forecast

No Data

MNKD MannKind

News

Comment

News

Announcement

All

Earnings Report

Related Transactions

Changes In Ownership

Major Events

Other